Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,085 across all filing types
Latest filing 2021-04-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
2020年度募集资金存放与使用情况鉴证报告
Regulatory Filings
2021-04-27 Chinese
[国枫]-易明医药2019年限制性股票激励计划首回购注销部分限制性股票事项的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the repurchase and cancellation of restricted shares under a 2019 restricted stock incentive plan of a company. It details the legal review, approvals, reasons, prices, quantities, and funding sources related to the repurchase and cancellation of shares. It is not a financial report, earnings release, or management discussion. It is a legal proceeding related document providing legal opinions on a specific corporate action (stock repurchase and cancellation under an incentive plan). Therefore, it fits best under Legal Proceedings Report (LTR). The document length is 6280 characters, which is substantive and contains detailed legal analysis, not just an announcement or certification, so it is not RNS or RPA.
2021-04-27 Chinese
关于回购注销2019年限制性股票激励计划部分限制性股票的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the repurchase and cancellation of restricted shares under the 2019 restricted stock incentive plan by the company 西藏易明西雅医药科技股份有限公司. It details the reasons for the repurchase, the number of shares involved, the repurchase price, approvals from board and supervisory meetings, and legal opinions. The document is a formal announcement of a share repurchase and cancellation event, not a financial report or earnings release. It fits the category of a Transaction in Own Shares (POS) filing, which covers company buybacks or cancellations of its own shares.
2021-04-27 Chinese
关于召开2020年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2020 Annual General Meeting (AGM) of the company 西藏易明西雅医药科技股份有限公司. It includes information about the meeting date, location, voting methods, agenda items to be discussed and voted on, instructions for shareholders on how to attend and vote, and proxy forms. The document does not contain the actual annual report or financial statements but rather the notification and procedural details for the AGM. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or notices about the AGM itself.
2021-04-27 Chinese
2020年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2020 年年度报告全文" which translates to "2020 Annual Report Full Text" for 西藏易明西雅医药科技股份有限公司. It contains detailed sections typical of an annual report, including company overview, financial data, business summary, management discussion and analysis, corporate governance, and financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes audited financial data, management statements, and comprehensive business and financial information for the fiscal year 2020. These characteristics align with the definition of an Annual Report (10-K). FY 2020
2021-04-27 Chinese
关于2020年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by the company through a public stock issuance. It includes specifics on the amount raised, the allocation and usage of these funds, changes in investment projects, compliance with regulatory requirements, and approvals by the board and shareholders. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it is titled as a "专项报告" (special report) on the annual storage and use of raised funds for the year 2020. This type of report aligns with disclosures related to capital raising and the management of those funds, which fits the category of Capital/Financing Update (CAP). The document is substantive, not merely an announcement or certification, and contains detailed financial and operational data about the capital raised and its deployment. Therefore, the appropriate classification is CAP with high confidence.
2021-04-27 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.